This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Media
-
Prof. Borje S. Andersson appointed Chief Medical Officer
Race Oncology Limited is pleased to announce that Professor Borje S. Andersson has agreed to join Race as Chief Medical Officer and Executive Director. Under this role, Prof. Andersson will be responsible for progressing Race’s clinical development plans for Bisantrene. He will continue to Chair Race’s Clinical Advisory Board and provide ongoing clinical guidance, leadership…
-
Race appoints clinical and FDA regulatory strategy advisor
Race Oncology is pleased to announce that it has appointed the clinical and regulatory strategy advisor, CCS Associates (CCSA, California, USA) to advise on development options for Bisantrene as an inhibitor of the Fat mass and obesity-associated protein (FTO). Recent preclinical studies by researchers at the City of Hope Hospital (ASX Announcement: 29 June 2020)…
-
Quia doloribus cupiditate sunt
Sit quasi velit. Fugiat dolorem sed corporis. Optio ad autem. Quo deleniti aspernatur omnis.
-
Race team talks about new leadership model
Our executive leaders discuss the benefits of a shared leadership model and the experience they each bring to Race Oncology.
-
Race leadership team strengthened
1 September 2020 – Race Oncology Limited (ASX: RAC) is pleased to announce that it has expanded its executive team with the appointment of Mr Phil Lynch as Chief Executive Officer and Managing Director. Effective immediately, Mr Lynch will share the executive leadership responsibilities with Dr Daniel Tillett, who will continue in his role of…
-
2020 Annual Report Summary
Dear Shareholders It is my pleasure to formally open the annual report to Race Oncology Shareholders for the period ended 30 June 2020. It’s been a highly successful year as regards progress in reframing the opportunity for Bisantrene in Acute Myeloid Leukemia (AML) and a range of other cancers. With the recently reported Phase II…
-
July 2020 Investor Update
Race Oncology is please update our shareholders on the clinical progress of bisantrene. This talk was presented by Race Oncology’s CSO Dr Daniel Tillett at the IRD Invest virtual conference on the 29th July 2019.
-
Race to present on 29 July at IRD Invest
22 July 2020 – Race Oncology Limited (ASX:RAC) is pleased to announce that Dr Daniel Tillett will present at the IRD Invest virtual investor conference on Wednesday, 29 July 2020 at 12.00 pm AEST. Dr Tillett will provide an update on the recent developments and future plans at Race Oncology. https://www.irdepartment.com.au/site/irdinvest The event is free to attend and…
-
Race reports impressive 40% response in Phase II Bisantrene AML Trial
On 16 July 2020, Race was pleased to report results of the investigator led Phase II trial of bisantrene for relapsed or refractory Acute Myleoid Leukaemia. This post summarises the highlights and provides access to key resources related to the data read out. Announcement highlights: Summary of resources: Investors are invited to access the following…